The existing tetrabenazine-based FDA-approved pharmacotherapies for use in HD largely target the reduction of choreic movements in HD through the inhibition of the vesicular monoamine transporter 2 (VMAT2), but they are insufficient to mitigate HD pathophysiology [210]. The gene discussed is SLC18A2; the disease is Huntington disease.